Orthobiologics company Kuros Biosciences has treated the first patient in a clinical trial comparing MagnetOs Putty to autograft for posterolateral spinal fusion.
Four details:
1. The study is implanting MagnetOs Putty on one side of the spine and autograft — the control material — on the other side.
2. Thirty patients will undergo a two-level instrumented posterolateral fusion.
3. The primary endpoint is the rate of posterolateral lumbar/thoracolumbar fusion, which is evaluated at 12 months.
4. MagnetOs Putty has a surface area that promotes bone growth throughout the graft for more predictable fusions, the company said in an April 13 news release.
Click here for more details on the study.
More articles on biologics:
Florida surgeon performs disc replacement on wrong area of patient's spine
2 spine surgeon leaders exit Johns Hopkins
5 high-profile device company court battles: Medtronic, Smith+Nephew & more